These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30833898)

  • 1. An
    Tanner L; Haynes RK; Wiesner L
    Front Pharmacol; 2019; 10():120. PubMed ID: 30833898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics.
    Knoll KE; Lindeque Z; Adeniji AA; Oosthuizen CB; Lall N; Loots DT
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34200519
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Knoll KE; van der Walt MM; Loots DT
    Microbiol Spectr; 2022 Apr; 10(2):e0231521. PubMed ID: 35352998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria.
    Watson DJ; Laing L; Beteck RM; Gibhard L; Haynes RK; Wiesner L
    Front Pharmacol; 2022; 13():957690. PubMed ID: 36091789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-mycobacterial activity of some medicinal plants used traditionally by tribes from Madhya Pradesh, India for treating tuberculosis related symptoms.
    Gupta VK; Kaushik A; Chauhan DS; Ahirwar RK; Sharma S; Bisht D
    J Ethnopharmacol; 2018 Dec; 227():113-120. PubMed ID: 30172059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
    Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
    Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of TB-Active Compounds in Murine Organs Relevant to Infection by
    Tanner L; Haynes RK; Wiesner L
    Front Pharmacol; 2020; 11():724. PubMed ID: 32508649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical, pharmacokinetic, efficacy and toxicity profiling of a potential nitrofuranyl methyl piperazine derivative IIIM-MCD-211 for oral tuberculosis therapy via in-silico-in-vitro-in-vivo approach.
    Magotra A; Sharma A; Singh S; Ojha PK; Kumar S; Bokolia N; Wazir P; Sharma S; Khan IA; Singh PP; Vishwakarma RA; Singh G; Nandi U
    Pulm Pharmacol Ther; 2018 Feb; 48():151-160. PubMed ID: 29174840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-mycobacterial Activity of 22 Iranian Endemic or Rare Plant Extracts Against Multi-drug and Extensively Drug-resistant
    Dehestani S; Davoodi J; Emami SA; Seddighinia FS; Sahebkar A; Soleimanpour S
    Comb Chem High Throughput Screen; 2022; 25(5):870-876. PubMed ID: 33588723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel nicotine analogues with potential anti-mycobacterial activity.
    Gandhi PT; Athmaram TN; Arunkumar GR
    Bioorg Med Chem; 2016 Apr; 24(8):1637-47. PubMed ID: 26951892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Identification of Novel Derivatives of Rifampicin Targeting Ribonuclease VapC2 of
    Maurya S; Jain A; Rehman MT; Hakamy A; Bantun F; AlAjmi MF; Singh V; Zehra A; Khan F; Haque S; Mishra BN
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.
    Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z
    Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Guéren.
    Ozeki Y; Igarashi M; Doe M; Tamaru A; Kinoshita N; Ogura Y; Iwamoto T; Sawa R; Umekita M; Enany S; Nishiuchi Y; Osada-Oka M; Hayashi T; Niki M; Tateishi Y; Hatano M; Matsumoto S
    PLoS One; 2015; 10(11):e0141658. PubMed ID: 26571296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
    Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
    Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.